As China steps up its investigations into alleged corruption at GlaxoSmithKline and other multinational pharmaceutical companies, China-based healthcare companies are also taking a major hit.
written on 27.05.2014
As China steps up its investigations into alleged corruption at GlaxoSmithKline and other multinational pharmaceutical companies, China-based healthcare companies are also taking a major hit.
See our Cookie Privacy Policy Here